Harish Seethapathy, M.B.,B.S.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hyponatremia | 4 | 2023 | 298 | 2.210 |
Why?
|
| Acute Kidney Injury | 11 | 2023 | 1968 | 2.140 |
Why?
|
| Nephritis, Interstitial | 4 | 2023 | 154 | 2.010 |
Why?
|
| Calciphylaxis | 3 | 2019 | 124 | 1.820 |
Why?
|
| Hypokalemia | 2 | 2022 | 153 | 1.520 |
Why?
|
| Nephrology | 2 | 2024 | 263 | 1.300 |
Why?
|
| Sodium | 5 | 2023 | 1622 | 1.030 |
Why?
|
| Myelinolysis, Central Pontine | 1 | 2023 | 18 | 0.930 |
Why?
|
| Hyperkalemia | 2 | 2023 | 218 | 0.900 |
Why?
|
| Hypernatremia | 1 | 2022 | 82 | 0.790 |
Why?
|
| Hyperammonemia | 1 | 2019 | 76 | 0.640 |
Why?
|
| Hyperparathyroidism, Secondary | 1 | 2019 | 126 | 0.630 |
Why?
|
| Glomerular Filtration Rate | 4 | 2023 | 2166 | 0.620 |
Why?
|
| Renal Replacement Therapy | 1 | 2019 | 257 | 0.580 |
Why?
|
| Research Personnel | 1 | 2021 | 573 | 0.540 |
Why?
|
| Mentors | 1 | 2021 | 631 | 0.540 |
Why?
|
| Career Choice | 1 | 2021 | 744 | 0.490 |
Why?
|
| Kidney | 5 | 2023 | 7184 | 0.460 |
Why?
|
| Kidney Failure, Chronic | 3 | 2020 | 2535 | 0.420 |
Why?
|
| Thyroiditis | 2 | 2021 | 85 | 0.390 |
Why?
|
| Emotions | 1 | 2022 | 2659 | 0.360 |
Why?
|
| Renal Dialysis | 4 | 2020 | 1783 | 0.360 |
Why?
|
| Thiosulfates | 2 | 2019 | 52 | 0.350 |
Why?
|
| Organ Transplantation | 1 | 2019 | 1140 | 0.330 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2021 | 2249 | 0.330 |
Why?
|
| Melanoma | 3 | 2022 | 5511 | 0.290 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2021 | 3143 | 0.280 |
Why?
|
| Biomedical Research | 1 | 2021 | 3309 | 0.260 |
Why?
|
| Prednisone | 2 | 2021 | 1574 | 0.260 |
Why?
|
| Kidney Neoplasms | 1 | 2021 | 4262 | 0.250 |
Why?
|
| Immunotherapy, Adoptive | 3 | 2022 | 1271 | 0.230 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 2022 | 1378 | 0.190 |
Why?
|
| Electrolytes | 1 | 2021 | 282 | 0.190 |
Why?
|
| Humans | 34 | 2024 | 744366 | 0.190 |
Why?
|
| Neoplasms | 4 | 2023 | 21696 | 0.190 |
Why?
|
| Oximes | 1 | 2022 | 311 | 0.180 |
Why?
|
| Nephritis | 1 | 2021 | 159 | 0.180 |
Why?
|
| Kidney Function Tests | 1 | 2022 | 683 | 0.180 |
Why?
|
| Pyrimidinones | 1 | 2022 | 370 | 0.170 |
Why?
|
| Sickle Cell Trait | 1 | 2019 | 81 | 0.170 |
Why?
|
| Water-Electrolyte Imbalance | 1 | 2020 | 113 | 0.170 |
Why?
|
| Chelating Agents | 1 | 2019 | 380 | 0.160 |
Why?
|
| Creatinine | 2 | 2023 | 1919 | 0.160 |
Why?
|
| Portasystemic Shunt, Transjugular Intrahepatic | 1 | 2019 | 95 | 0.160 |
Why?
|
| Potassium | 1 | 2022 | 1336 | 0.150 |
Why?
|
| Parathyroidectomy | 1 | 2019 | 235 | 0.150 |
Why?
|
| Pyridones | 1 | 2022 | 711 | 0.150 |
Why?
|
| Retrospective Studies | 10 | 2023 | 77460 | 0.150 |
Why?
|
| Thrombophilia | 1 | 2019 | 305 | 0.140 |
Why?
|
| Postoperative Complications | 1 | 2019 | 15297 | 0.140 |
Why?
|
| Renal Insufficiency, Chronic | 2 | 2021 | 2200 | 0.140 |
Why?
|
| Imidazoles | 1 | 2022 | 1206 | 0.130 |
Why?
|
| Microvessels | 1 | 2019 | 544 | 0.130 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2023 | 2540 | 0.130 |
Why?
|
| Proton Pump Inhibitors | 1 | 2019 | 526 | 0.120 |
Why?
|
| Patient Participation | 1 | 2024 | 1457 | 0.120 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2021 | 1856 | 0.100 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2022 | 2043 | 0.100 |
Why?
|
| Anemia, Sickle Cell | 1 | 2019 | 1020 | 0.100 |
Why?
|
| Hip Fractures | 1 | 2019 | 955 | 0.100 |
Why?
|
| Artificial Intelligence | 1 | 2024 | 2213 | 0.090 |
Why?
|
| Middle Aged | 12 | 2021 | 213390 | 0.090 |
Why?
|
| Pyrazoles | 1 | 2020 | 1972 | 0.090 |
Why?
|
| Aged | 11 | 2023 | 163288 | 0.080 |
Why?
|
| Hematologic Neoplasms | 1 | 2020 | 1832 | 0.080 |
Why?
|
| Graft vs Host Disease | 1 | 2020 | 2958 | 0.070 |
Why?
|
| Risk Factors | 5 | 2021 | 72296 | 0.070 |
Why?
|
| Wounds and Injuries | 1 | 2019 | 2400 | 0.070 |
Why?
|
| Immunotherapy | 1 | 2021 | 4446 | 0.070 |
Why?
|
| Incidence | 2 | 2021 | 20952 | 0.060 |
Why?
|
| Male | 12 | 2023 | 350115 | 0.060 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2022 | 5445 | 0.060 |
Why?
|
| Anticoagulants | 1 | 2019 | 4600 | 0.060 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2022 | 11525 | 0.060 |
Why?
|
| Aged, 80 and over | 4 | 2021 | 57776 | 0.060 |
Why?
|
| Positron-Emission Tomography | 1 | 2019 | 6234 | 0.060 |
Why?
|
| Clinical Trials as Topic | 1 | 2019 | 7914 | 0.060 |
Why?
|
| Skin Neoplasms | 2 | 2020 | 5692 | 0.050 |
Why?
|
| Baclofen | 1 | 2023 | 129 | 0.050 |
Why?
|
| Digoxin | 1 | 2023 | 250 | 0.050 |
Why?
|
| Cystatin C | 1 | 2023 | 250 | 0.050 |
Why?
|
| Treatment Outcome | 3 | 2023 | 63107 | 0.050 |
Why?
|
| Vancomycin | 1 | 2023 | 501 | 0.040 |
Why?
|
| Adrenal Gland Diseases | 1 | 2020 | 138 | 0.040 |
Why?
|
| Female | 10 | 2021 | 380193 | 0.040 |
Why?
|
| Urogenital Neoplasms | 1 | 2020 | 137 | 0.040 |
Why?
|
| Water-Electrolyte Balance | 1 | 2020 | 346 | 0.040 |
Why?
|
| Mutation | 1 | 2022 | 29786 | 0.040 |
Why?
|
| Myositis | 1 | 2020 | 251 | 0.040 |
Why?
|
| Carcinoma, Merkel Cell | 1 | 2020 | 303 | 0.030 |
Why?
|
| Interleukin-2 | 1 | 2023 | 1904 | 0.030 |
Why?
|
| Hypothyroidism | 1 | 2020 | 658 | 0.030 |
Why?
|
| Nitriles | 1 | 2020 | 955 | 0.030 |
Why?
|
| International Classification of Diseases | 1 | 2019 | 867 | 0.030 |
Why?
|
| Hemoglobins | 1 | 2019 | 1532 | 0.030 |
Why?
|
| Myocarditis | 1 | 2020 | 771 | 0.030 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2019 | 2016 | 0.020 |
Why?
|
| Recovery of Function | 1 | 2021 | 2926 | 0.020 |
Why?
|
| Cohort Studies | 2 | 2023 | 40559 | 0.020 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2019 | 1790 | 0.020 |
Why?
|
| Acute Disease | 1 | 2019 | 7147 | 0.020 |
Why?
|
| Prognosis | 2 | 2019 | 29060 | 0.020 |
Why?
|
| Pneumonia | 1 | 2020 | 2133 | 0.020 |
Why?
|
| Disease Management | 1 | 2019 | 2460 | 0.020 |
Why?
|
| Boston | 1 | 2021 | 9312 | 0.020 |
Why?
|
| Pyrimidines | 1 | 2020 | 2943 | 0.020 |
Why?
|
| Hemorrhage | 1 | 2019 | 3461 | 0.020 |
Why?
|
| Adult | 4 | 2023 | 214052 | 0.020 |
Why?
|
| Head and Neck Neoplasms | 1 | 2020 | 2736 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2019 | 9145 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2019 | 5101 | 0.020 |
Why?
|
| Age Factors | 1 | 2019 | 18373 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2019 | 21748 | 0.010 |
Why?
|
| Time Factors | 1 | 2021 | 40075 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 2020 | 13104 | 0.010 |
Why?
|